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Amyloid β peptide-induced inhibition of
endothelial nitric oxide production involves
oxidative stress-mediated constitutive eNOS/HSP90
interaction and disruption of agonist-mediated
Akt activation
Folami Lamoke1†, Valeria Mazzone2†, Tiziana Persichini2, Annamaria Maraschi3, Michael Brennan Harris4,
Richard C Venema5, Marco Colasanti2, Micaela Gliozzi6, Carolina Muscoli6,7, Manuela Bartoli1 and Vincenzo Mollace6,7*
Abstract
Background: Amyloid β (Aβ)-induced vascular dysfunction significantly contributes to the pathogenesis of
Alzheimer’s disease (AD). Aβ is known to impair endothelial nitric oxide synthase (eNOS) activity, thus inhibiting
endothelial nitric oxide production (NO).
Method: In this study, we investigated Aβ-effects on heat shock protein 90 (HSP90) interaction with eNOS and Akt
in cultured vascular endothelial cells and also explored the role of oxidative stress in this process.
Results: Treatments of endothelial cells (EC) with Aβ promoted the constitutive association of HSP90 with eNOS
but abrogated agonist (vascular endothelial growth factor (VEGF))-mediated HSP90 interaction with Akt. This effect
resulted in blockade of agonist-mediated phosphorylation of Akt and eNOS at serine 1179. Furthermore, Aβ stimulated
the production of reactive oxygen species in endothelial cells and concomitant treatments of the cells with the
antioxidant N-acetyl-cysteine (NAC) prevented Aβ effects in promoting HSP90/eNOS interaction and rescued
agonist-mediated Akt and eNOS phosphorylation.
Conclusions: The obtained data support the hypothesis that oxidative damage caused by Aβ results in
altered interaction of HSP90 with Akt and eNOS, therefore promoting vascular dysfunction. This mechanism,
by contributing to Aβ-mediated blockade of nitric oxide production, may significantly contribute to the cognitive
impairment seen in AD patients.
Introduction
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder [1] characterized by the accumulation of
intracellular neurofibrillary tangles and extracellular senile
plaques of which the major component is the amyloid β
peptide (Aβ) [2,3]. Although the molecular mechanisms
leading to neuronal damage in AD have not been com-
pletely understood, it is well established that increased
production of Aβ, in soluble and/or aggregate form, is a
key causative event for AD [3,4].
A growing body of evidence has indicated that the
cerebral vasculature is an important target of Aβ and
that vascular dysfunction significantly contributes to neur-
onal damage and dementia [5,6]. AD patients have re-
duced cerebral blood flow. This precedes dementia and
may contribute to its progression. Recently, it has been
shown that endothelin-1 is elevated in Alzheimer’s disease
and upregulated by amyloid β [7]. Cardiovascular risk fac-
tors, especially hypertension, have been associated with
higher risk of developing Alzheimer’s disease, partially
through cerebral vasculature impairment and reduced
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nitric oxide production [8]. The brains of patients with
AD exhibit elevated levels of ACE, Ang-II, and angioten-
sin II receptors (AR-II) [9].
In addition, decreased endothelium-derived nitric oxide
(NO) bioavailability and vascular dysfunction have been
demonstrated in AD [10-15].
NO production at the endothelial cell level involves the
activity of the enzyme endothelial nitric oxide synthase
(eNOS, NOS III), which is constitutively expressed and
produces NO in a calcium-dependent manner [16]. In
models of chronic brain hypoperfusion, in vivo administra-
tion of Aβ has been shown to increase the expression of
eNOS and, paradoxically, to decrease endothelium-derived
NO formation [8], thus, suggesting that Aβ could affect
the activity of this enzyme. eNOS post-translational modi-
fication, including phosphorylation at specific amino acid
residues, can profoundly affect its activity and, therefore,
influence NO production [17]. Furthermore, eNOS associ-
ation with a specific set of interacting proteins has been
shown to critically regulate its enzymatic activity by exert-
ing both stimulatory and/or inhibitory effects [18-21]. In
particular, the chaperone molecule heat shock protein 90
(HSP90) has been demonstrated to possess a key stimula-
tory role by maintaining the enzyme in an active conform-
ational state and by facilitating its phosphorylation at
serine 1177/1179 [22-24]. Aβ has been shown to inhibit
eNOS phosphorylation at serine 1177/1179 and at other
residues [25,26], however, no information is available about
the effects of Aβ on eNOS interaction with HSP90 or other
regulatory partners, which could potentially contribute to
these inhibitory effects. In addition, increased production
of reactive oxygen species (ROS) and consequent oxidative
stress have been shown to negatively influence eNOS ac-
tivity and significantly contribute to vascular dysfunction
in a number of cardiovascular diseases including diabetes
and hypertension [23-30]. Aβ-induced oxidative stress has
been extensively documented [31-33]; however, its direct
contribution to the reported effects in inhibiting eNOS-
dependent NO production or in influencing its interaction
with regulatory proteins is not clear.
In this study, we show that in bovine aortic endothelial
cells soluble Aβ1–42 promotes the constitutive associ-
ation of HSP90 with eNOS. This effect resulted in block-
ade of agonist-mediated phosphorylation of Akt and
eNOS at serine 1179. These effects are correlated with
Aβ’s ability to increase the production of hydroxyl radi-
cals in endothelial cells and are reverted by concomitant
treatment with the antioxidant N-acetyl-cysteine.
Materials and methods
Materials
All tissue culture reagents were from Invitrogen (Carlsbad,
CA, USA), unless otherwise specified. Fetal bovine serum
(FBS) was from Gemini Bio-products (Woodland, CA,
USA). Aβ25–35, Aβ35–25, Aβ1–42, and Aβ42–1 peptides, as
well as nitro-L-arginine methyl ester (L-NAME), were
from Sigma-Aldrich (St. Louis, MO, USA). Monoclonal
and polyclonal anti-eNOS and anti-HSP90 antibodies
were from BD-Transduction Laboratories (San Diego, CA,
USA). The polyclonal antibody for phospho-eNOS (Ser
1179) was from Invitrogen (Grand Island, NY, USA). Poly-
clonal and monoclonal antibodies for anti-Akt and
phospho-Akt (Ser473) were purchased from Cell Signaling
(Danvers, MA, USA). Protein A/G agarose beads were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
The ECL chemiluminescence detection assay as well
as the peroxidase-conjugated anti-mouse/anti-rabbit IgG
were from Amersham Biosciences (Piscataway, NJ, USA).
The cGMP enzyme-immunoassay kit was from Cayman
Chemical Co. (Ann Arbor, MI, USA). The blots were
reprobed after stripping using a stripping solution from
Pierce (Rockford, IL, USA).
Cell cultures and treatments conditions
Primary cultures of bovine aortic endothelial cells (BAEC)
and brain endothelial cells (BBEC) were purchased from
VEC Technologies (Rensselaer, NY, USA) or the endothelial
cell Core Facility of the Vascular Biology Center at Georgia
Regents University. BAEC were cultured in medium M199
in the presence of 10% FBS, 1% glutamine, 1% penicillin/
streptomycin, and 1% non-essential amino acid and vita-
min mixtures. The cells were used between passages 3
and 5. Oligomeric preparations of Aβ peptides (25–35,
35–25, 1–42, or 42–1) were prepared by re-suspension in
serum-free medium, left overnight at room temperature,
then sonicated before supplementation to the culture
medium as described previously [34].
The cells were pretreated for 24 h with 1 μM Aβ25–35,
1 μM Aβ35–25, 5 μM Aβ1–42, and 5 μM Aβ42–1. These
doses of Aβ and the time of exposure were chosen based
on preliminary experiments testing maximal effects (data
not shown). After pre-incubation the cells were stimu-
lated with 20 ng/ml vascular endothelial growth factor
(VEGF) for established time points. Rat aortic smooth
muscle cells (RASMC) were also obtained from VEC
Technologies and used between passages 2 to 5 for the
cGMP experiments. The RASMC cultures were maintained
in DMEM (Invitrogen, Grand Island, NY, USA) containing
10% FBS and 1% penicillin/streptomycin.
Nitric oxide production
Nitric oxide release in BAEC was measured by cGMP
reporter cell assay following a protocol modified from
Ishii et al. [35,36]. Confluent BAEC and RASMC were
serum-starved for 16 to 18 h and then incubated in
Locke’s buffer (154 mM NaCl, 5.6 mM KCl, 2 mM CaCl2,
1 mM MgCl2, and 10 mM Hepes, pH7.4) for at least
20 min before the experiment. The BAECs were then
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stimulated with 20 ng/ml VEGF for 30 min and, after
stimulation, the bathing medium was rapidly transferred to
the confluent RASMC, let incubate for 3 min, then the
cells were lysed in ice-cold 20-mM sodium acetate,
pH 4.0. The cGMP concentration in RASMC treated with
the BAEC conditioned medium was determined using an
enzyme immunoassay kit following the manufacturer’s
instructions.
Determination of reactive oxygen species formation
The production of reactive oxygen species in endothelial
cells, following the different treatments, was determined
by a fluorimetric assay using 2,7-dihydrochlorofluores-
cein (DHCF) from Invitrogen (Grand Island, NY, USA).
BAEC, and BBEC plated in 96-well plates, were cultured
for 24 h in serum-free condition and in presence or
absence of Aβ. After this time, the cells were incu-
bated with 5 μM DHCF for 1 h. The hydroxyl radi-
cals produced in response to the different treatments
oxidize the DHCF and generate its oxidation fluores-
cent product dichlorofluorescein (DCF). The fluores-
cence intensity was measured with a multi-detection
microplate reader (BioTek, Winooski, VT, USA) using
an excitation and emission light at 485 nm and 535 nM,
respectively. Some samples were also incubated in the
presence of 50 U of cell permeable superoxide dismutase
(PEG-SOD from Sigma-Aldrich, Saint Louis, MO, USA),
which was used as negative control to assess the specificity
of the assay.
Immunoprecipitation and Western blotting
Western blotting analysis was performed as previously
described [37,38]. Briefly, BAEC and BBEC were lysed
with a modified RIPA buffer (20 mM Tris–HCl (pH 7.4),
2.5 mM EDTA, 50 mM NaF, 10 mM Na4P2O7, 1% Tri-
ton X-100, 0.1% sodium dodecyl sulphate, 1% sodium
deoxycholate,1 mM PMSF, and 2 mM Na3VO4). The
samples were then subjected to SDS-PAGE electrophor-
esis and immunoblotted on nitrocellulose (Schleicher &
Schuell Biosciences Inc., Keene, NH, USA). Protein-protein
interaction was determined by immunoprecipitation ana-
lysis performed as previously described [37,38]. For these
experiments, the cells were lysed with a buffer containing:
25 mM Tris–HCl (pH 7.4), 2.5 mM EDTA, 50 mM NaF,
10 mM Na4P2O7, 1% Triton X-100, 1 mM PMSF, and
2 mM Na3VO4. The cell lysates were allowed to react over-
night with the primary antibody and the immunocom-
plexes were then precipitated with pre-cleared protein A/
G agarose beads. After washing three times with ice-cold
washing buffer (0.1% Triton X-100 in TBS) the beads and
the immunocomplexes were precipitated by centrifuga-
tion, solubilized by resuspension in 2X SDS-sample buffer
and by boiling at 100°C for 5 min. All the densitometry
units have been normalized against total enzyme for each
lane and are expressed as the ratio of phosphorylated pro-
teins to total.
Results
Aβ blocks eNOS phosphorylation at serine 1179 and
eNOS-dependent NO production
We selected two amyloid β peptides to conduct our ex-
periments: Aβ25–35, the shortest fibrillar fragment typic-
ally used in culture based on its capability of retaining
the toxicity of the full length Aβ (1-40/42) peptides [39],
and Aβ1–42, the disease-associated fragment found in pa-
tients with AD [40]. BAEC were cultured for 24 h in the
presence of 10 μM Aβ25–35 or 5 μM Aβ1–42 and then
challenged with 20 ng/ml VEGF for different time points
(0, 5, 15, and 30 min). Figure 1A,B shows the Western
blotting analysis determining phospho-serine 1179-eNOS
formation in response to VEGF stimulation in BAEC
cultured in the presence or absence (control) of Aβ25–35
(Figure 1A) or Aβ1–42 (Figure 1B). Densitometric analysis
was used to quantify the obtained data and to assess
statistical significance of the results (Figure 1A,B). VEGF
induced a time-dependent increase in eNOS phosphoryl-
ation at serine 1179 in control cells, but this effect was
completely blocked by the pre-treatment of the cells for
24 h with 10 μM Aβ25–35 or 5 μM Aβ1–42. To test for the
specificity of inhibitory activities of Aβ25–35/Aβ1–42 on
phosphorylation of eNOS, BAEC were treated with the re-
versed inactive peptides Aβ35–25 (Figure 1C) and Aβ42–1
(Figure 1D). As shown in Figure 1C,D, VEGF-induced
eNOS phosphorylation at serine 1179 was unaffected by
the treatment with Aβ35–25 or Aβ42–1, thus proving that
eNOS inhibition was specifically elicited by the Aβ25–35
and Aβ1–42 sequence derived from the amyloid precursor
protein. Next, to establish whether Aβ25–35/Aβ1–42 effects
on serine 1179 phosphorylation resulted in impairment
of eNOS activity, we evaluated cGMP formation as a
measure of NO production by eNOS in a cell reporter
assay. The obtained data are summarized in Figure 1E.
The treatment with Aβ25–35 or Aβ1–42 reduced the
amount of cGMP generated by RASMC incubated with
the BAEC-conditioned medium by over 80% (P < 0.05,
n = 4) (Figure 1E). This latter directly correlates with the
amount of NO generated by the BAEC in response to
VEGF stimulation. To control for the specificity of the
cGMP assay, some BAEC cells were incubated in the
presence of 100 μM of NOS inhibitor L-NAME be-
fore VEGF stimulation (Figure 1E). These data showed
that the pretreatment of BAEC with L-NAME pre-
vented an accumulation of cGMP in RASMC. The
incubation of BAEC pre-treated with Aβ25–35 and Aβ1–42
with L-NAME resulted in further decrease in cGMP for-
mation in RASMC (Figure 1E) suggesting that multiple
signaling pathways contribute to eNOS activation by
VEGF.
Lamoke et al. Journal of Neuroinflammation  (2015) 12:84 Page 3 of 14
Figure 1 (See legend on next page.)
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Aβ stimulates constitutive eNOS/HSP90 complex
formation
eNOS activity is also influenced by its interaction with a
specific set of regulatory proteins. Therefore, it is pos-
sible that Aβ peptides could alter the process of eNOS
interaction with its regulatory partners. We tested this
possibility and focused our attention on the chaperone
molecule HSP90. In Figure 2, the results of the immuno-
precipitation study assessing HSP90/eNOS complex for-
mation are summarized. Specific immunoreactivity for
HSP90 found in the protein complex immunoprecipi-
tated by anti-eNOS antibody was increased in response to
VEGF stimulation, thus indicating that VEGF stimulation
of BAEC promoted the interaction of HSP90 with eNOS.
This interaction, which peaked at 15 and 30 min after
VEGF treatment (Figure 2A,B), was enhanced by the pre-
treatment for 24 h with 10 μM Aβ 25–35 and 5 μM Aβ 1–42
and was also induced at the basal level as compared to
untreated control cells (0 min on Figure 2A,B), thus sug-
gesting that Aβ promotes the formation of eNOS/HSP90
complex in a constitutive manner. Consistently, specific
immunoreactivity for eNOS was detected in response to
VEGF treatment in a time-dependent manner in the pro-
tein complex immunoprecipitated by anti-HSP90 antibody
(Figure 2C,D). The pre-treatment with either Aβ pro-
moted eNOS/HSP90 interaction at the basal level (0 min)
and further stimulated eNOS/HSP90 complex formation
after stimulation with VEGF (Figure 2C,D).
Aβ stimulates reactive oxygen species production
Aβ has been shown to promote reactive oxygen species
production and oxidative stress in vivo and in vitro. At
the same time, oxidative damage has been involved in im-
pairment of eNOS-dependent NO production and vascular
dysfunction. To test the hypothesis that oxidative stress
could be involved in Aβ effects on eNOS phosphorylation
pattern or its interaction with HSP90, we first determined
Aβ25–35/Aβ1–42 effects on production of superoxide anion
in endothelial cells. Figure 3 illustrates the results obtained
from a fluorimetric analysis measuring dichlorofluorescein
(See figure on previous page.)
Figure 1 Western blotting analysis showing VEGF-stimulated (20 ng/ml for 0 to 30 min) eNOS phosphorylation at serine 1179 in BAECs cultured for
24 h in the presence (black bars) or absence (control, white bars) of 10 μM Aβ25–35 (A) and 5 μM Aβ1–42 (B). Blots were subjected to densitometric
analysis and the obtained data were analyzed for statistical significance (*P < 0.01 versus 0 min control group, n = 3). (C-D) Western blotting
analysis demonstrating VEGF-stimulated eNOS phosphorylation at serine 1179 in BAECs cultured for 24 h in the presence of reversed inactive 10 μM
Aβ35–25 (C) and 5 μM Aβ42–1 (D). (E) Endothelial nitric oxide release. cGMP formation in BAECs cultured for 24 h in the presence (black bars) or absence
(white bars) of 10 μM Aβ25–35 and 5 μM Aβ1–42 and following stimulation with 20 ng/ml VEGF for 30 min. cGMP formation, which directly reflects the
nitric oxide release, was determined by reporter cell assay by measuring picomoles of cGMP generated in rat aortic smooth muscle cells after 3 min of
exposure of the cells to media of BAECs after the different treatments, as indicated above and as explained in the text. To assess the assay specificity,
some experiments were conducted with BAECs pre-stimulated with 100 μM of the nitric oxide synthase inhibitor L-NAME (LN). (*P < 0.05 versus
control, n = 4, #P < 0.05 versus VEGF, n = 4). VEGF, vascular endothelial growth factor; eNOS, endothelial nitric oxide synthase; min, minutes.
Figure 2 Immunoprecipitation studies showing time-dependent eNOS/HSP90 complex formation in response to stimulation with 20 ng/ml VEGF
in BAECs cultured for 24 h in the presence or absence (control) of 10 μM Aβ25–35 (A-C) and 5 μM Aβ1–42 (B-D). (A-B) Immunoprecipitation was
carried-out with anti-eNOS antibody and the immunoprecipitated proteins were blotted with antibody against anti-HSP90. (C-D) Immunoprecipitation
was carried-out with anti-HSP90 antibody and the immunoprecipitated proteins were blotted with antibody against anti-eNOS. VEGF, vascular
endothelial growth factor; eNOS, endothelial nitric oxide synthase; min, minutes; Hsp90, heat shock protein 90.
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(DCF) formation in BAEC cultured for 24 h in the pres-
ence of 10 μM Aβ25–35 or 5 μM Aβ1–42 in comparison to
BAEC cultured in the presence of an equivalent dose of
the reverse peptides Aβ35–25 and Aβ42–1 or control BAEC
cultured in normal medium in the absence of Aβ. The
conversion of 2,7-dihydrochlorofluorescein (DCHF) to the
fluorescent compound dichlorofluorescein (DCF) is dir-
ectly correlated to the amount of superoxide and hydroxyl
radicals generated in the cells. Aβ25–35 and Aβ1–42 caused
twofold increase (P < 0.001, n = 6) in ROS formation as
compared with control BAEC, but this effect was not ob-
served in cells cultured in the presence of the reversed in-
active peptides Aβ35–25 or Aβ1–42 (Figure 3). In addition,
Aβ25–35/Aβ1–42 induced ROS production was inhibited by
the concomitant treatment of the cells with 2 mM of the
antioxidant N-acetyl-cysteine (NAC), confirming the speci-
ficity of the fluorescent signal.
Aβ effects on eNOS phosphorylation are blocked by
N-acetyl cysteine
Because of the observed ability of Aβ25–35/Aβ1–42 to
augment the production of ROS in endothelial cells, we
further tested whether antioxidants could prevent the
effects of Aβ25–35 and Aβ1–42 in altering eNOS phos-
phorylation/activation pattern. BAEC were cultured for
24 h with 10 μM Aβ25–35 or 5 μM Aβ1–42 in the presence
or absence of 2 mM NAC. Western blotting analysis was
then conducted to determine the phosphorylation of
eNOS at serine 1179 in response to stimulation with
20 ng/ml VEGF for 5, 15, and 30 min (Figure 4). As shown
in Figure 4A,B, NAC treatment restored a normal pat-
tern of eNOS phosphorylation at serine 1179 following
VEGF stimulation, thus abolishing the inhibitory effect of
Aβ25–35 and Aβ1–42. Densitometric analysis of the ob-
tained results is plotted in Figure 4C,D where these data
are compared to those shown in Figure 1A,B to assess
statistical significance.
NAC disrupts enhanced eNOS/HSP90 association by Aβ
Next then we determined the effects of the antioxidant
NAC on Aβ25–35/Aβ1–42 induction of eNOS/HSP90 com-
plex formation. As in the previous experiments (Figure 2)
and as shown in Figure 5, treatment of the BAEC with
NAC prevented the ability of Aβ25–35 (Figure 5A,C) and
Aβ1–42 (Figure 5B,D) to promote HSP90/eNOS complex
formation under basal conditions (0 min) and also re-
stored an association pattern similar to that induced by
VEGF in BAEC cultured under normal conditions without
Aβ25–35 or Aβ1–42.
Aβ inhibits VEGF-stimulated Akt phosphorylation at
Ser473 and Akt/eNOS interaction
It is known that VEGF activation stimulates the protein
kinase, Akt, and its subsequent phosphorylation/activa-
tion leads to the eNOS phosphorylation at Ser1179 [41] as
detected in Figure 1. To determine whether Aβ affected
the signaling cascade of Akt, we first investigated the ef-
fects of Aβ on Akt-Ser473 phosphorylation (Figure 6). As
expected, VEGF significantly increased the phosphoryl-
ation of Akt-Ser473 in control cells. The phosphorylation
of Akt peaked from 5 to 15 min and after 30 min was un-
detectable (Figure 6). The addition of Aβ25–35 (Figure 6)
or Aβ1–42 (Figure 6B) resulted in the complete interrup-
tion in the sequential phosphorylation of Akt, which
Figure 3 Effects of Aβ peptides (Aβ25–35/Aβ1–42 = active, Aβ35–25/Aβ42–1 = reverse, inactive) on superoxide anion production in BAECs assessed by
dichloro-dihydrofluoresceindiacetate (DHCF-DA) fluorimetric assay. Some samples were pre-treated with 2 mM of the anti-oxidant N-acetyl-cysteine
(NAC) to determine assay specificity. (*P < 0.001 versus control, n = 6).
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occurred in parallel to the disruption of eNOS activation
observed previously (Figure 1A,B,E). Concurrently, we
identified specific immunoreactivity for Akt in the pro-
tein complex immunoprecipitated by an anti-eNOS
antibody which increased in response to VEGF stimu-
lation (Figure 7A,B). This interaction peaked at 5 min
after VEGF stimulation but was lost with the pre-treatment
with Aβ25–35 (Figure 7A) and Aβ1–42 (Figure 7B) for 24 h.
Consistent with those data, specific immunoreactivity for
eNOS was detected in the protein complex immunopre-
cipitated by anti-Akt antibody after 5 min of VEGF
stimulation (Figure 7C,D). The pre-treatment with ei-
ther Aβ led to the loss of eNOS/Akt interaction. Ob-
tained results validate that VEGF stimulation of BAEC
promotes the interaction of Akt with eNOS and sug-
gest that Aβ-induced blockade of eNOS activity and
NO production involves the alteration in Akt/eNOS
regulation.
NAC recovers Aβ-induced Akt phosphorylation
We examined the effects of NAC on Akt phosphorylation at
Ser473 by Western blotting when stimulated with 20 ng/ml
VEGF for 5, 15, and 30 min. Treatment with the antioxidant
NAC re-established the previously identified pattern of Akt
phosphorylation following VEGF stimulation (Figure 8A,B).
To assess statistical significance, the densitometric analysis
data are compared to those shown in Figure 6A,B and the
obtained results are plotted in Figure 8C,D.
Aβ perturbs Akt/HSP90 association
The replacement of HSP90 with its associated proteins
can be critical to the regulation of those proteins, as
demonstrated in studies that showing that nitrated lipid,
OLA-NO2, enhances eNOS/Hsp90 interaction by re-
placing the eNOS/cav1 interaction, resulting in increas-
ing eNOS activity [42]. We sought to determine whether
an Aβ-induced augmentation of eNOS/HSP90 had an
Figure 4 Representative Western blotting showing phosphorylation of eNOS at serine 1179 in response to stimulation with 20 ng/ml VEGF
of BAECs cultured for 24 h in the presence of 10 μM Aβ25–35 (A) or 5 μM Aβ1–42 (B) in combination with 2 mM NAC. (C-D) The blots
were subjected to densitometric analysis, and the obtained data were analyzed for statistical significance in comparison to the data
shown in Figure 1A,B. (*P < 0.05 versus 0 min of each separate treatment group, n = 3). VEGF, vascular endothelial growth factor; eNOS,
endothelial nitric oxide synthase; min, minutes; NAC, N-acetyl-cysteine.
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effect on Akt/HSP90. Our results show that both Aβ
peptides block the basal ratio of VEGF-mediated Akt/
HSP90 interaction at 5 min, the critical time point iden-
tified earlier as the window for Akt phosphorylation
(Figure 9A,C and Figure 10A,C, red boxes). NAC effect-
ively thwarts this abrogation, restoring Akt/HSP90 associ-
ation to exceed a threshold where Akt activation can occur
(Figure 9B,C and Figure 10B,C). To assess statistical signifi-
cance, the densitometric analysis data are compared to
those shown in Figures 9 and 10A,B and the obtained re-
sults are plotted in Figures 9 and 10C.
Discussion
Endothelial production of nitric oxide is critical to the
maintenance of vascular tone and the blood brain barrier,
as well as to the anti-inflammatory and anti-thrombotic
properties of the vascular endothelium [27]. Altered eNOS-
dependent NO production results in endothelial dysfunc-
tion, which is associated with cardiovascular disease and
has been shown to play a pathogenic role in AD [7,27].
In this study, we demonstrated that exogenous admin-
istration of the biologically active fragments Aβ25–35 and
Aβ1–42 to cultured endothelial cells results in the pro-
duction of reactive oxygen species (Figure 3), blockade
of agonist-stimulated phosphorylation of eNOS at serine
1179 and decreased NO production (Figure 1). These ef-
fects correlated with Aβ-induced promotion a constitu-
tive interaction of eNOS with its regulatory partner
HSP90 (Figure 2). This correlated with a decrease in the
interaction of HSP90 with Akt, the kinase responsible
Figure 5 Immunoprecipitation analysis showing eNOS/HSP90 complex formation (as in Figure 2) in response to stimulation with 20 ng/ml VEGF
of BAECs cultured in the presence of Aβ25–35 (A) and 1 μM Aβ1–42 (B) for 24 h and in combination with 2 mM NAC. (C-D) The blots were subjected to
densitometric analysis, and the obtained data were analyzed for statistical significance in comparison to the data showed in Figure 2A,B. (*P < 0.05
versus 0 min of each separate treatment group and #P < 0.02 versus 0 min of untreated control cells (white bars), n = 4). VEGF, vascular endothelial
growth factor; eNOS, endothelial nitric oxide synthase; min, minutes; NAC, N-acetyl-cysteine; Hsp90, heat shock protein 90.
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Figure 6 Representative Western blotting and densitometric analysis showing Akt phosphorylation at serine 473 in BAECs after stimulation with
VEGF 20 ng/ml for 0 to 30 min. BAECs were cultured for 24 h in the presence (black bars) or absence (control, white bars) of 10 μM Aβ25–35
(A) and 5 μM Aβ1–42 (B). Data were analyzed for statistical significance (*P < 0.01 versus 0 min control group, n = 3). VEGF, vascular
endothelial growth factor.
Figure 7 Immunoprecipitation studies showing time-dependent eNOS/Akt complex formation in response to stimulation with 20 ng/ml VEGF
(0 min) in BAECs cultured for 24 h in the presence or absence (control) of 10 μM Aβ25–35 (A-C) and 5 μM Aβ1–42 (B-D). (A-B) Immunoprecipitation was
carried-out with anti-eNOS antibody, and the immunoprecipitated proteins were blotted with antibody against anti-Akt. (C-D) Immunoprecipitation
was carried-out with anti-Akt antibody, and the immunoprecipitated proteins were blotted with antibody against anti-eNOS. VEGF, vascular endothelial
growth factor; eNOS, endothelial nitric oxide synthase; min, minutes.
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eNOS phosphorylation at Set1179 (Figure 9). These ob-
served alterations appear to be the result of oxidative
damage because the concomitant treatment of the cells
with the antioxidant N-acetyl cysteine reverts Aβ effects
restoring a normal pattern of eNOS phosphorylation at
serine 1179 and interaction with HSP-90 (Figures 4 and 8).
Our data demonstrated for the first time an inverse effect
of Aβ on HSP90/eNOS interaction and HSP90/Akt inter-
action. We confirmed that upon stimulation with VEGF,
Akt phosphorylates eNOS in an HSP90-dependent man-
ner; synergistically increasing eNOS activity (Figures 1, 6,
and 7). Once Aβ is introduced to these conditions, there is
a diminished interaction between HSP90 and Akt, sug-
gesting that the chaperone remains bound to eNOS in a
manner that facilitates its inability to sufficiently bind Akt
to signal its phosphorylation at Ser473 (Figures 9 and 10).
Although the partial loss of this interaction could occur
from other unexplored mechanisms, such as loss of the
overall HSP90 protein level previously demonstrated as
an effect of Aβ stimulation [43], it is reasonable to
conclude that blocking the effects of Aβ can restore
this interaction. In fact, when treated with NAC, HSP90/
Akt interaction returns to basal levels and the detection
of phospho-Akt (Ser473) indicate that this kinase over-
comes the effects of Aβ in the presence of an antioxi-
dant (Figures 9 and 10).
The results of our study strongly support the growing
evidence that vascular dysfunction is involved in the eti-
ology of AD dementia. Indeed, severe vascular changes,
such as microvascular degeneration and breakdown of
the blood brain barrier, have been demonstrated in AD
patients [44]. In addition, Aβ can be found both in the
brain parenchyma and in the cerebral vasculature of AD
patients together with increased presence of monocytes/
Figure 8 Representative Western blotting showing phosphorylation of Akt at serine 473 in response to stimulation with 20 ng/ml VEGF of BAECs
cultured for 24 h in the presence of 10 μM Aβ25–35 (A) or 5 μM Aβ1–42 (B) in combination with 2 mM NAC. (C-D) The blots were subjected to
densitometric analysis, and the obtained data were analyzed for statistical significance in comparison to the data shown in Figure 2A,B. (*P < 0.05
versus 0 min of each separate treatment group, n = 3). VEGF, vascular endothelial growth factor; eNOS, endothelial nitric oxide synthase; min,
minutes; NAC, N-acetyl-cysteine.
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Figure 9 Akt/HSP90 complex formation detected by immunoprecipitation analysis in response to stimulation with 20 ng/ml VEGF of BAECs cultured in
the presence of Aβ25–35 (A) for 24 h and in combination with 2 mM NAC (B). Densitometric analysis of the blots analyzed for statistical significance are
reported in the bar graphs (C) (*P< 0.05 versus 0 min of each separate treatment group and #P< 0.02 versus 0 min of untreated control cells (white bars),
n =4). VEGF, vascular endothelial growth factor; eNOS, endothelial nitric oxide synthase; min, minutes; NAC, N-acetyl-cysteine; HSP90, heat shock protein 90.
Figure 10 Akt/HSP90 complex formation detected by immunoprecipitation analysis in response to stimulation with 20 ng/ml VEGF of BAECs cultured in
the presence of Aβ1–42 (A) for 24 h and in combination with 2 mM NAC (B). Densitometric analysis of the blots analyzed for statistical significance are
reported in the bar graphs (C) (*P< 0.05 versus 0 min of each separate treatment group and #P< 0.02 versus 0 min of untreated control cells (white bars),
n= 4). VEGF, vascular endothelial growth factor; eNOS, endothelial nitric oxide synthase; min, minutes; NAC, N-acetyl-cysteine; HSP90, heat shock protein 90.
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macrophages in the vessel wall and activated microglial
cells in the parenchyma [45,46].
To date, attention has been focused on the molecular
mechanisms by which Aβ and/or its fragments exert their
effect on cells. The assumption that amyloid deposits are
typically extracellular accounts for an effect at the level of
the plasma membrane, possibly receptor-mediated. How-
ever, intracellular Aβ accumulation has been observed in
various cell types, including neurons and endothelial cells
[47-49]. In particular, it is not clear whether the effect of
Aβ on eNOS activity initiates with the extracellular Aβ de-
position or results from Aβ intracellular accumulation.
In this respect, reports have shown that internalized
Aβ prevents eNOS from utilizing NADPH [49], a co-
factor required for the activity of the enzyme. Further-
more, other studies have shown that over-expression of
Aβ in endothelial cells or administration of exogenous
(extracellular) Aβ on isolated vessels, blunts agonist-mediated
eNOS activation and its phosphorylation at serine 1177/
1179 [25,26]. Although these studies provide critical infor-
mation, it is not clear if the aberrant intracellular produc-
tion of Aβ peptides is a primary event in endothelial cells
or if acute administration of extracellular Aβ represents
the condition seen in AD patients that are chronically ex-
posed to Aβ. It is tempting to speculate that both obser-
vations may be considered true and complementary.
In particular, acute oxidative-independent effects of intra-
or extracellular Aβ on eNOS activity may be transient, but
could result in elevation of reactive oxygen species and in
the oxidative-dependent chronic effects that we observe
after 24 h of exposure.
Interestingly, our data show that Aβ promotes eNOS/
HSP90 complex formation in a constitutive manner, pro-
viding a novel and important information. Previous work
demonstrated that disruption of HSP90 interaction with
eNOS results in inhibition of this enzymatic activity
[22,50], therefore, one could expect that in the condition
of vascular dysfunction the interaction of eNOS with its
chaperone would be inhibited. However, this does not ap-
pear to be the case, as has been also shown in a model of
diabetes [51]. Several reports have demonstrated enhanced
HSP90 expression as part of the cellular response to oxi-
dative stress conditions [52-54]. Specifically, the pathology
of AD is characterized by enhanced heat shock proteins
expression and activity in response to aberrant ‘misfolded’
proteins [55]. Of interest, HSP90 expression is induced by
Aβ in glial cells which participate in the Aβ clearance
process [56]. Our results demonstrate that Aβmight induce
similar effects in endothelial cells. Moreover, HSP90 has
been demonstrated to inhibit O2− production by NOS iso-
forms [57,58], thus the enhancement of HSP90 interaction
with eNOS, as shown by our results (Figure 2), could be a
compensatory response to maintain the enzyme in a func-
tional state in oxidative stress conditions when the risk of
eNOS uncoupling is higher. However, this fails to occur,
suggesting that other mechanisms are involved in this
process and may be critical to the ability of HSP90 to
regulate eNOS activity.
The evidence provided by our study extends and sup-
ports previous work demonstrating that Aβ promotes
vascular dysfunction by impairing eNOS-dependent NO
production. Furthermore, our study underscores the role
of oxidative stress in the dysfunctional effects of Aβ on
eNOS activity and function.
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